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a  b  s  t  r  a  c  t
Disorder-speciﬁc  cognitive  behavior  therapy  (DS-CBT)  is effective  at treating  major  depressive  disorder
(MDD)  while  transdiagnostic  CBT  (TD-CBT)  addresses  both  principal  and  comorbid  disorders  by tar-
geting  underlying  and  common  symptoms.  The  relative  beneﬁts  of these  two  models  of  therapy  have
not  been  determined.  Participants  with  MDD  (n = 290)  were  randomly  allocated  to  receive  an  internet
delivered  TD-CBT  or  DS-CBT  intervention  delivered  in  either  clinician-guided  (CG-CBT)  or self-guided
(SG-CBT)  formats.  Large  reductions  in  symptoms  of  MDD  (Cohen’s  d  ≥ 1.44;  avg.  reduction  ≥ 45%)  and
moderate-to-large  reductions  in  symptoms  of comorbid  generalised  anxiety  disorder  (Cohen’s  d  ≥ 1.08;
avg.  reduction  ≥ 43%),  social  anxiety  disorder  (Cohen’s  d  ≥  0.65;  avg.  reduction  ≥  29%)  and  panic  dis-
order  (Cohen’s  d ≥ 0.45;  avg.  reduction  ≥ 31%)  were found.  No marked  or consistent  differences  wereransdiagnostic
isorder-speciﬁc
elf- guided
herapist-guided
nternet
4-month follow-up
observed  across  the  four  conditions,  highlighting  the efﬁcacy  of  different  forms  of CBT  at treating  MDD
and  comorbid  disorders.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).andomized controlled trial
. Introduction
Major depressive disorder (MDD) is a chronic and disabling dis-
rder estimated to affect 5% of the world’s population each year
Kessler et al., 2009). Both clinical and subclinical levels of depres-
ion are associated with considerable burden and economic costs
or individuals and to the broader society (Üstün et al., 2004). MDD
s frequently comorbid with anxiety disorders and comorbidity is
ssociated with greater distress, disability (Andrews et al., 2002),
ncreased service utilisation (Burgess et al., 2009), and a greater risk
f suicide (Norton et al., 2008).Psychological treatments such as cognitive behavioural therapy
CBT) are effective at treating MDD  and anxiety disorders (Butler
t al., 2006; Cuijpers et al., 2008; Stewart & Chambless, 2009). CBT
∗ Corresponding author at: eCentreClinic, Department of Psychology, Macquarie
niversity, New South Wales, Australia. Fax: +61 2 9850 8062.
E-mail address: blake.dear@mq.edu.au (B.F. Dear).
ttp://dx.doi.org/10.1016/j.janxdis.2015.08.002
887-6185/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).interventions are generally designed to be disorder-speciﬁc (DS-
CBT) and to target the cognitive and behavioural symptoms of the
principal disorder with which a patient presents. Although DS-CBT
is known to reduce the severity of comorbid anxiety and depressive
disorders (Brown et al., 1995; Tsao et al., 2002; Craske et al., 2007;
Titov et al., 2009), it is unclear whether this is the most efﬁcient
treatment approach.
Several alternative approaches have been developed to address
comorbid symptoms, including tailored and transdiagnostic treat-
ments. Tailored approaches modify the treatment according to
patient characteristics and comorbidities (Carlbring et al., 2011).
The ﬁrst empirical study of a tailored approach demonstrated treat-
ment superiority over control conditions across several measures
of anxiety, depression, and quality of life, in participants with
anxiety disorders, with results sustained at two year follow-up
(Carlbring et al., 2011). A subsequent study extended these results
by demonstrating that a tailored approach produced at least equiv-
alent results to a standard approach in the treatment of depression
comorbid with anxiety disorders (Johansson et al., 2012).
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Transdiagnostic CBT (TD-CBT) is an alternative treatment
pproach that aims to simultaneously address both principal and
omorbid disorders by targeting underlying and common symp-
oms (Mansell et al., 2009; Wilamowska et al., 2010). This approach
s based on the notion that many of the common psychological
isorders share characteristics including common symptoms, over-
ll course, response to treatment and temperamental antecedents
Barlow et al., 2004; Goldberg, 2010; Murray et al., 2014; Talkovsky
 Norton, 2014), and therefore may  respond to treatment that is not
ailored to each speciﬁc diagnosis (McEvoy et al., 2009).
By virtue of involving a single treatment protocol TD-CBT offers
dvantages of efﬁciency over DS-CBT. Emerging evidence from
ncontrolled trials and randomised controlled trials (RCTs) indi-
ates that TD-CBT is clinically effective (Dear et al., 2011; Johnston
t al., 2011; Farchione et al., 2012; Titov et al., 2013) relative to
ontrol conditions. However, to date, only one RCT has directly
ompared TD-CBT with DS-CBT (Norton & Barrera, 2012). In that
tudy, 46 people were randomly allocated to receive a TD-CBT
roup treatment, or to different DS-CBT treatments speciﬁcally
or social phobia (SP), generalized anxiety disorder (GAD), or for
anic disorder (PD) also administered in group format, with the
peciﬁc treatment group determined by the person’s principal dis-
rder. Using non-inferiority analyses, no differences were found
n beneﬁts from either approach at post-treatment, indicating the
otential of the TD-CBT approach. Importantly, while these prelim-
nary results are promising, the conclusions that can be drawn from
he existing evidence base are constrained by small sample sizes,
nd limited availability of follow-up data. Large sample sizes will
acilitate a more reliable evaluation of the relative impact of TD-CBT
nd DS-CBT on principal and comorbid disorders, while longer term
ollow-ups provide the opportunity to explore the stability of gains
nd the relative beneﬁts of each approach in reducing subsequent
ulnerability to emotional disorders.
The present study is the ﬁrst in a series of RCTs that aim to sys-
ematically explore the relative beneﬁts of TD-CBT vs. DS-CBT for
eople with symptoms of four common mental disorders, by tar-
eting one disorder in each RCT, in the case of the present study,
DD. The disorders of interest in these RCTs include MDD, gen-
ralized anxiety disorder (GAD), social anxiety/phobia disorder
SP), and panic disorder (PD). To facilitate comparison, the TD-
BT and DS-CBT interventions were designed to comprise a similar
tructure, present similar amounts of information, and require a
imilar amount of therapist contact. However, where the DS-CBT
ntervention focussed explicitly and solely on treatment of MDD
ith MDD-speciﬁc content, skills, examples and vignettes, the TD-
BT intervention focussed on the management of both anxiety
nd mood symptoms generally without reference to any speciﬁc
isorder or symptoms. The secondary aim of the present study
as to explore how such interventions may  be most efﬁciently
elivered. To date, most studies of TD-CBT interventions have eval-
ated treatment protocols comprising ≥10 treatment sessions. It
s questionable, however, whether public health services have the
esources and capacity to routinely deliver psychological treat-
ents in this way.
Several lines of research have explored alternate delivery meth-
ds for psychological treatments. One line of research has reported
hat online psychological treatments may  be effectively delivered
y a technician, who is supervised and supported by a regis-
ered therapist. Several studies have empirically evaluated this
odel, and have found clinically signiﬁcant improvements when
reatment is delivered by technicians in iCBT interventions for
epression (Titov et al., 2010), GAD (Robinson et al., 2010), and anx-
ety disorders (Johnston et al., 2011; Johnston et al., 2013). Another
romising line of research has reported that self-guided delivery of
D-CBT and DS-CBT can result in signiﬁcant clinical improvements
Meyer et al., 2009; Berger et al., 2011; Titov et al., 2013). How-isorders 35 (2015) 88–102 89
ever, to date, the relative beneﬁts of the therapist and self-guided
approaches have not been directly compared. It should be noted
that the use of the term self-guided treatment in the present study
refers to treatment which is preceded by an initial interview with
a therapist, and may  involve subsequent interviews, although no
planned contact during treatment. There is evidence to indicate that
this model of self-guided treatment should be differentiated from
fully automated self-guided treatments (Christensen et al., 2006;
Klein et al., 2011), which may  not include interviews or monitoring,
and may  result in more modest outcomes (Johansson & Andersson,
2012).
To explore these aims, we compared clinician-guided (CG-CBT)
vs. self-guided (SG-CBT) versions of TD-CBT and DS-CBT interven-
tions, delivered over eight weeks. Based on evidence indicating
that those seeking treatment via the internet have similar char-
acteristics to people with similar disorders identiﬁed in national
epidemiological studies (Titov et al., 2010) and evidence indicating
that outcomes of internet and face-to-face treatments are similar
(Andersson & Hedman, 2013) the recruitment of the sample and
delivery of the interventions occurred via the internet with people
across Australia. This methodology also reﬂects growing recogni-
tion of the beneﬁts of internet-delivered psychological treatments
as evidenced by the public funding of national internet-delivered
mental health services (Andrews et al., 2010; Andersson & Titov,
2014; Titov et al., in press). It was  hypothesized that TD-CBT and
DS-CBT would be associated with signiﬁcant reductions in principal
symptoms of MDD, but that TD-CBT would be superior at reduc-
ing symptoms of comorbid GAD, SP and PD at each time point. It
was also hypothesised that CG-CBT would be superior to SG-CBT at
every time point for symptoms of the four target disorders.
2. Method
2.1. Participants
The study was  approved by the Human Research Ethics Com-
mittee (HREC) of Macquarie University, Sydney, Australia, and the
trial was registered on the Australian and New Zealand Clinical
Trials Registry (ANZCTR) as ACTRN12612000421831. The study
was promoted via advertisements in major newspapers across
Australia and via unpaid general advertisements by a broad range
of non-governmental organisations providing services to people
with mental health difﬁculties. This study was advertised alongside
three other studies with the same design, with each RCT targeting
people with one of four principal diagnoses, that is, MDD, GAD,
PD or SAD. Participants read about the study and applied to par-
ticipate via the website of the eCentreClinic (www.ecentreclinic.
org), which is a specialist research unit offering the opportunity to
receive free treatment via the internet. Interested individuals were
invited to submit an online application to participate in the trial,
which involved completing several symptom questionnaires, and
providing basic demographic information and contact details.
The inclusion criteria for the study were: (i) resident of Australia
aged 18–64 years of age; (ii) a principal complaint of depression
symptoms; (iii) total score ≥5 on the Patient Health Questionnaire-
9 (PHQ-9) (Kroenke et al., 2001); and (iv) if taking medication for
anxiety or depression, being on a stable dose for at least one month.
The exclusion criteria were: (i) experiencing an unmanaged psy-
chotic illness; (ii) experiencing very severe symptoms of depression
i.e., deﬁned as a total score >22 or endorsing a score >2 to item 9
of the Patient Health Questionnaire 9-item (PHQ9); (iii) having a
history of self-harm or suicide attempts within the last 12 months;
or (iv) currently participating in CBT.
The CONSORT ﬂowchart for this trial is shown in Fig. 1. A total
of 568 people applied to participate in the trial and indicated that
90 N. Titov et al. / Journal of Anxiety Disorders 35 (2015) 88–102
pplic
s
a
wFig. 1. Participant ﬂow from aymptoms of MDD  were their principal difﬁculty during the online
pplication process. Of these, 452 met  the initial inclusion criteria,
hich were assessed via the online application, and then partici-ation to 24-month follow-up.pated in a telephone interview during which the Mini International
Neuropsychiatric Interview Version 5 (MINI) (Lecrubier et al., 1997)
was administered and the inclusion criteria re-assessed. A further
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2 applicants initially indicated principal difﬁculties of GAD, SP,
r PD during the online application but, upon interview, indicated
DD was their principal difﬁculty. A total of 310 applicants met  all
nclusion criteria following the telephone interview.
.2. Design and measures
The study employed a CONSORT-revised compliant RCT where
articipants were randomised to receive one of two  treatment
pproaches (Treatment Approach: TD-CBT vs DS-CBT) and one of
wo support formats (Support Format: CG-CBT vs. SG-CBT). All
articipants completed questionnaires at initial assessment, pre-
reatment, post-treatment and at 3, 12, and 24-month follow-
p. The primary and secondary measures were administered at
ach time point with the exception of the PDSS-SR, which due
o an administrative error was not administered at initial assess-
ent but was administered at all other time-points. In addition,
he GAD-7 and PHQ-9 were also administered weekly during the
reatment. To reduce burden on participants the tertiary outcomes
ere not administered at initial assessment and the K-10 and NEO-
F-N were not administered at 24-month follow-up. All analyses,
xcept those for the PDSS-SR and the tertiary measures, used the
nitial assessment scores as baseline. Unblinded MINI diagnostic
ssessments were conducted via telephone at initial assessment
nd again at 3-month follow-up. The study was powered for com-
arisons between the two treatment approaches and between the
wo delivery formats. The researchers sought to recruit at least 102
articipants for each comparison arm (i.e., TD-CBT vs DS-CBT and
G-CBT vs SG-CBT) which, with alpha set at 0.05 and power set
t 0.80, would enable the detection of small-to- moderate effect
ize differences between the arms (i.e., Cohen’s ds > .35). How-
ver, more participants were recruited to address both expected
reatment withdrawal and questionnaire non-response at post-
reatment time points.
.2.1. Primary measure
.2.1.1. Patient Health Questionnaire 9-Item Scale (PHQ-9; Kroenke
t al., 2001). The PHQ-9 is a 9-item measure of symptoms of depres-
ion based on the DSM-IV diagnostic criteria for major depressive
isorder (Kroenke et al., 2001). The PHQ-9 has good internal con-
istency (Titov et al., 2011) and is sensitive to change (Kroenke et
l., 2010). Scores range from 0 to 27 and Cronbach’s  in this study
as .82.
.2.2. Secondary measures
.2.2.1. Generalized Anxiety Disorder 7-Item Scale (GAD-7; Spitzer
t al., 2006). The GAD-7 is a 7-item measure of the symptoms and
everity of general anxiety, which is based on the DSM-IV diagnos-
ic criteria for GAD (Löwe et al., 2008). The GAD-7 has good internal
onsistency and good convergent and divergent validity with other
nxiety and disability scales (Kroenke et al., 2010; Dear et al., 2011
cores range from 0 to 21 and Cronbach’s  in the current study
as .88.
.2.2.2. Mini-Social Phobia Inventory (MINI-SPIN; Connor et al.,
001). The 3-item MINI-SPIN is a measure of social anxiety symp-
oms based on DSM-IV criteria for social anxiety disorder (Connor et
l., 2001; Weeks et al., 2007). The MINI-SPIN has good internal con-
istency and adequate convergent validity with other standardised
easures of social anxiety (Weeks et al., 2007; Osório et al., 2010).
cores range from 0 to 12 and Cronbach’s  in this study was .87..2.2.3. Panic Disorder Severity Scale - Self Report (PDSS-SR; Houck
t al., 2002). The PDSS-SR is a 7-item measure of panic disor-
er symptoms. Psychometric evaluations suggest that it has high
nternal consistency, good test-retest reliability and is sensitive toisorders 35 (2015) 88–102 91
treatment-related change (Houck et al., 2002). Scores range from 0
to 28 and Cronbach’s  in the current study was .93.
2.2.3. Tertiary measures
2.2.3.1. Kessler 10-Item Scale (K-10; Kessler et al., 2002). The K-10
is a ten-item measure of general psychological distress with total
scores ≥22 associated with a diagnosis of anxiety and depressive
disorders (Andrews & Slade, 2001). Scores range from 0 to 50 and
Cronbach’s  in the current study was  .89.
2.2.3.2. Sheehan Disability Scale (SDS; Sheehan, 1983). The SDS is a
3-item measure of disability with high internal consistency (Leon
et al., 1997). Scores range from 0 to 30 and Cronbach’s  in the
present study was  .89.
2.2.3.3. NEO Five Factor Inventory - Neuroticism Subscale (NEO-FFI-
N; Costa & McCrae, 1985). The Neuroticism subscale of the NEO is
a 12-item measure of a general tendency to experience negative
emotional states and sensitivity to stress (Clark et al., 1994; Grifﬁth
et al., 2010), which is considered a higher-order risk factor for anx-
iety and depression (Cuijpers et al., 2005; Spinhoven et al., 2009).
Scores range from 0 to 48 and Cronbach’s  in the current study
was .75.
2.2.4. Other measures
2.2.4.1. Mini International Neuropsychiatric Interview, version 5.0.0
(MINI; Lecrubier et al., 1997). The MINI is a brief diagnos-
tic interview developed to determine the presence of current
Axis-I disorders using DSM-IV diagnostic criteria. It has excel-
lent inter-rater reliability and adequate concurrent validity with
the Composite International Diagnostic Interview (World Health
Organization, 1990).
2.2.5. Treatment satisfaction and acceptability
Consistent with previous research (Titov et al., 2013; Dear et al.,
2015), treatment satisfaction and acceptability was assessed at
post-treatment via two questions: (1) ‘Would you feel conﬁdent
in recommending this treatment to a friend?’ and (2) ‘Was it worth
your time doing the Course?’. Participants responded to these ques-
tions with a ‘Yes’ or ‘No’ response.
2.3. Interventions
All participants received access to either a DS-CBT course for
MDD, the Mood Course, or a TD-CBT course, the Wellbeing Course.
The Mood Course was  developed speciﬁcally for this trial and
the Wellbeing Course has been previously demonstrated as clin-
ically efﬁcacious in treating symptoms of anxiety and depression
(Titov et al., 2012; Titov et al., 2013; Titov et al., 2014). The two
courses were based on the Macquarie University Model (MUM) of
internet-delivered CBT, which was developed over a large num-
ber of clinical trials by the eCentreClinic research group, and
which is associated with high completion rates, strong clinical
outcomes, and high participant satisfaction. Characteristics of this
model include a high level of treatment structure, a combination
of didactic teaching methods with detailed clinical case narra-
tives, scaffolded content which builds in detail over the course
of treatment, homework assignments designed to facilitate skill
acquisition, systematic release of materials over a pre-deﬁned
period of treatment, and regular and protocolised support provided
by a combination of clinician contact via telephone or email as well
as via automated emails and short message service prompts that
encourage the practice of skills and their adoption into day-to-day
routines.
To facilitate comparisons the two courses comprise a simi-
lar structure and similar amounts and forms of content. Both
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nclude 5 lessons delivered online over 8 weeks, lesson summaries
nd homework assignments for each lesson, a similar number of
etailed case stories, and a similar number of additional resources
argeting symptoms such as sleep problems and communication
kills. Each lesson is presented in a slide format combining text
nd images, with approximately 60 slides per lesson and 50 words
er slide. Participants are instructed to read lessons in order over
 weeks. Lessons 1, 2, 3, 4, and 5 are available at the beginning of
eeks 1, 2, 4, 5, and 7, respectively. This timetable provides partici-
ants with additional time for the most complex components of the
ntervention; namely skills for managing cognitive and behavioural
ymptoms.
Consistent with standard deﬁnitions (McEvoy et al., 2009), the
D-CBT intervention was the same for all participants and was  not
esigned to treat any speciﬁc psychological disorder and rather
imed to present a broad range of therapeutic information and
kills relevant to the cognitive, physical and behavioural symp-
oms of psychological distress generally. Reﬂecting this, the TD-CBT
ntervention did not mention speciﬁc diagnoses and all vignettes,
xamples and case stories were presented to cover a broad range
f situations and types of psychological distress (e.g., excessive
orry, low mood, social anxieties and panic and strong physi-
al sensations). In contrast, the DS-CBT treatment was  speciﬁcally
esigned to target symptoms of MDD  and presented all therapeu-
ic information and skills in the context of MDD  and reducing MDD
ymptoms. Consequently, all vignettes, examples and case stories
ocussed on MDD  and the management of associated symptoms
nd no speciﬁc mention of other diagnoses or the broader appli-
ation of therapeutic skills was made. The content and differences
etween the TD-CBT and DS-CBT interventions are summarised in
able 2.
Participants in the clinician-guided condition (CG-CBT) received
eekly contact from a psychologist using telephone or a secure
mail messaging system. Three accredited and nationally regis-
ered psychologists provided treatment and all had either Masters
egrees or Doctoral Degrees in clinical psychology. Based on the
ndings of previous studies (Craske et al., 2009; Johnston et al.,
011) and to minimise therapist drift (Waller, 2009), the nature of
he contact was protocolised and key aims included (1) reinforcing
he main messages of each lesson, (2) answering questions, (3)
einforcing progress and skills practice, (4) problem solving the
se of skills, (5) normalising the challenges of recovery, and (6)
btaining feedback about the participant’s perception and engage-
ent with the course. Each contact was designed to take ≤10 min,
ut more time was provided when clinically indicated. The psy-
hologists received training in online interventions via the training
rogram at the eCentreClinic and received supervision from BFD
nd NT during weekly individual and group supervision sessions.
articipants in the self-guided condition did not receive weekly
ontact, but were monitored throughout treatment by the clini-
ians and were able to contact the clinic if technical assistance
as required or if they were experiencing a mental health crisis.
 research assistant provided technical support for all participants
n the trial.
All participants received an email at the start of the intervention
ith guidelines about the course and a recommended timetable for
orking through the materials. Consistent with previous research
Titov et al., 2013; Titov et al., 2014), all participants also received
utomated emails at the beginning of each week to inform them
bout additional resources and to recommend activities for that
eek. All participants also received automatic emails that rein-
orced their progress, congratulated them on the completion of
essons, and reminded them about the availability of new materials
hen they had not viewed them within a week of them becoming
vailable.isorders 35 (2015) 88–102
2.4. Statistical analyses
All analyses were conducted using SPSS version 21. Group dif-
ferences in demographic variables and diagnostic variables were
analysed using binomial and multinomial logistic regression and
general linear models analyses. The alpha signiﬁcance level for the
preliminary analyses was  adjusted from 0.05 to 0.01 as a partial
control for the large number of analyses conducted. Participants
who did not start the interventions were not included in any anal-
yses.
The generalised estimation model (GEE) modelling technique
was employed to examine changes in the symptom measures over
time. GEE emphasizes the modelling of change in an average group
effect over time while accounting for within-subject variance with
the speciﬁcation of a working correlation structure. Rather than
creating conditional interpretation with the use of individual inter-
cepts or random slopes, as in traditional mixed linear models, the
primary emphasis in GEE is to directly model the average group-
related change over time (Hubbarb et al., 2010). An exchangeable
working correlation structure and maximum likelihood estimation
was selected, coupled with a robust error estimation for the pur-
poses of model parsimony, for all GEE analyses. All GEE  models also
speciﬁed a gamma  distribution with a log link response scale to
address positive skewness in the dependent variable distributions.
Importantly, in the GEE analyses, the model coefﬁcients represent
multiplicative change in the dependent variable from baseline;
these coefﬁcients result in a change factor (i.e., exp()), which can
be used to calculate the average percentage change of symptoms
from baseline. Consistent with the principles of intention-to-treat
analyses, separate GEE models utilising random intercepts were
employed to impute missing data. The same approach was used for
the imputation of the missing binary diagnostic values. Speciﬁcally,
probability values were imputed based on an individual’s initial
diagnostic status combined with time by treatment condition esti-
mates and cases demonstrating higher cumulative probability than
the baseline value being imputed as having a diagnosis.
To maximise power and the interpretability of results, the two
Treatment Approaches and the two Support Formats were ana-
lysed separately; however, to ensure these analyses did not obscure
important patterns within the data, all higher order interactions
were explored ﬁrst. Following these initial explorations, a system-
atic series of analyses were employed to comprehensively compare
the two  treatment approaches (TD-CBT vs. DS-CBT) and the two
support formats (CG-CBT vs. SG-CBT). First, to explore efﬁcacy
across symptom domains, GEE analyses were conducted on the pri-
mary and secondary outcome variables from baseline to 24-month
follow-up focussed on the four symptom domains (i.e., depres-
sion, generalised anxiety, social anxiety and panic) among those
meeting MINI diagnostic criteria for the related disorder (i.e., MDD,
GAD, SAD and PAN) at assessment. Second, to explore efﬁcacy in
terms of general psychological distress, disability and neuroticism,
GEE analyses were conducted on the tertiary outcomes from base-
line to 24-month follow-up using the overall sample data. Third,
for the binary outcome variable of diagnostic status, GEE analy-
ses were conducted using a binary scale and logit link function
implementing quasi-likelihood probability estimates at each time
point between groups. Fourth, to examine the overall cumulative
reduction in comorbid diagnoses, the average count of comorbid
diagnoses was analysed over time and between groups with a
negative binomial probability distribution and a log link function.
Finally, to explore acceptability and satisfaction, one-way factorial
ANOVAs and chi-square analyses were conducted on the lesson
completion and treatment satisfaction data. For comparison and
benchmarking purposes, Cohen’s d effect sizes and 95% conﬁdence
intervals were calculated for the within-group and between-group
effects based on the estimated marginal means derived from the
N. Titov et al. / Journal of Anxiety Disorders 35 (2015) 88–102 93
Table  1
Demographic characteristics of the participants.
Treatment Approach Support Format
Overall
(n = 290)
TD-CBT
(n = 149)
DS-CBT
(n = 141)
Signiﬁcance CG-CBT
(n = 145)
SG-CBT
(n = 145)
Signiﬁcance
Gender
Male 82
(28%)
41
(28%)
41
(29%)
Wald’s 2 = .09,
p = .768
39
(27%)
43
(30%)
Wald’s 2 = .27,
p = .602
Female 208
(72%)
108
(72%)
100
(71%)
106
(73%)
102
(70%)
Age  (years)
Mean (SD) 44.19
(11.75)
43.84
(11.71)
44.55
(11.81)
Wald’s 2 = .27,
p = .605
44.87
(11.29)
43.50
(12.18)
Wald’s 2 = .99,
p = .320
Range  18–64 18–63 19–64 18–63 19–64
Marital status
Single/never married 79
(27%)
41
(28%)
38
(27%)
Wald’s 2 = .35,
p = .552
34
(23%)
45
(31%)
Wald’s
2 = 1.06,
p = .302
Married/de facto 174
(60%)
92
(62%)
82
(58%)
93
(64.14%)
81
(56%)
Separated/divorced/widowed 37
(13%)
16
(11%)
21
(15%)
18
(12%)
19
(13%)
Education
High  school or less 46
(16%)
25
(17%)
21
(15%)
Wald’s 2 = .11,
p = .738
21
(14%)
25
(17%)
Wald’s 2 = .11,
p = .738
Trade/technical certiﬁcate 57
(20%)
29
(19%)
28
(20%)
33
(23%)
24
(17%)
Diploma/degree 187
(64%)
95
(64%)
92
(65%)
91
(63%)
96
(66%)
Employment
Full-time/part-time 214
(74%)
107
(72%)
107
(76%)
Wald’s 2 = .89,
p = .347
99
(68%)
115
(79%)
Wald’s
2 = 4.47,
p = .034
Student 15
(5%)
6
(4%)
9
(6%)
9
(6%)
6
(4%)
Unemployed, retired or disabled 61
(21%)
36
(24%)
25
(18%)
37
(26%)
24
(17%)
Previous mental health treatment 204 107 97 Wald’s 2 = .32, 99 105 Wald’s 2 = .59,
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Currently taking medication 107
(37%)
52
(35%)
55
(39%)
EE models. The average percentage change across time was  also
alculated from the GEE analyses for each of the outcome variables
ith 95% conﬁdence intervals.
. Results
.1. Preliminary analyses
.1.1. Baseline differences
Demographic and diagnostic characteristics of the sample are
hown in Table 1. Speciﬁc details of participant ﬂow, treat-
ent attrition, lesson completion and questionnaire response are
hown in Fig. 1. Preliminary analyses did not reveal any differ-
nces between the TD-CBT and DS-CBT groups or the CG-CBT and
G-CBT groups at baseline (ps ≥ .05). Comparisons exploring dif-
erences between participants completing and not completing the
uestionnaires at post-treatment indicated no differences on the
emographic variables reported in Table 1 or in baseline outcome
easure scores (ps ≥ .05).
.1.2. Clinician time
There were signiﬁcant differences in clinician contact timeetween CG-CBT and SG-CBT groups (F1,288 = 262.68, p < .001). The
ean clinician time per participant in CG-CBT group was 29.51 min
SD = 20.39), which comprised answering and making calls (total
alls = 796; range = 0–10 calls; mean time = 20.59; SD = 20.96), asp = .574 (68%) (72%) p = .441
Wald’s 2 = .53,
p = .469
52
(36%)
55
(38%)
Wald’s 2 = .11,
p = .715
well as reading, sending and responding to secure emails (total
emails = 861; range = 0–12 emails; mean time = 8.92; SD = 6.31). The
mean total clinician time per participant for SG-CBT was  .91 min
(SD = 1.982), which comprised answering and making calls (total
calls = 3; range = 0–1 call; mean time = .07; SD = .51), as well as read-
ing, sending and responding to secure emails (total emails = 68;
range = 0–4 emails; mean time = .84; SD = 1.93). This contact was
focused on assessing and managing mental health crises rather than
the provision of treatment or course-related clinical support. No
signiﬁcant differences were found between the TD-CBT and DS-CBT
in the amount of clinician time required (F1,288 = .32, p = .58).
3.1.3. Preliminary test for higher order interactions
The GEE analyses revealed non-signiﬁcant Treatment Approach
by Support Format by Time interactions for all outcomes (GAD-7:
Wald’s 2 = 2.22, p = .649; PHQ-9: Wald’s 2 = 1.31, p = .859; MINI-
SPIN: Wald’s 2 = 1.86, p = .761; PDSS-SR: Wald’s 2 = 5.14, p = .273;
K10: Wald’s 2 = 1.01, p = .797; SDS: Wald’s 2 = 1.00, p = .909)
except one (NEO-FFI-N: Wald’s 2 = 14.34, p = .002). Further analy-
ses revealed that participants receiving self-guided transdiagnostic
treatment reported a very small reduction in neuroticism scores
from 12-month to 24-month follow-up (exp = 0.865, p = .012),
which was not observed in those participants receiving clinician-
guided transdiagnostic treatment or self-guided or clinician-guided
disorder speciﬁc treatment. However, given the very large num-
ber of comparisons needed to identify this change and the fact the
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Table 2
Therapeutic content and skills included within the Transdiagnostic Wellbeing Course and Disorder-Speciﬁc Mood Course.
Transdiagnostic Wellbeing Course Disorder-Speciﬁc Mood Course
Lesson Lesson Content Primary Skills Taught Additional Resources Lesson Content Primary Skills Taught Additional Resources
1 Education about the general prevalence
and symptoms of anxiety and low mood
without mention of speciﬁc disorders.
Introduction of a CBT model and
explanation of the functional relationship
between physical, thought and behavioural
symptoms in psychological distress.
Instructions for identifying their own
symptoms and how their symptoms
interact. Transdiagnostic vignettes and
examples of anxiety and low mood
symptoms provided.
– Symptom
identiﬁcation
– Symptom
formulation
– Sleep management
–  What to do in a mental
health emergency
– Transdiagnostic Case Stories
Education about the prevalence and
symptoms of MDD. Introduction of a
CBT model and explanation of the
functional relationship between
physical, thought and behavioural
symptoms in MDD. Instructions for
identifying their own  symptoms and
how their symptoms interact. MDD
speciﬁc vignettes and examples of
MDD  symptoms provided.
– Symptom
identiﬁcation
– Symptom
formulation
– Sleep management
–  What to do in a
mental health
emergency
– MDD Case Stories
2  Introduction to the basic principles of
cognitive therapy and importance of
managing thoughts to manage anxiety and
low mood. Instructions for monitoring and
challenging thoughts related to anxiety
and low mood. Transdiagnostic vignettes
and examples of thoughts provided.
– Thought monitoring
–  Thought challenging
– Structured problem solving
–  Worry time
– Challenging beliefs
– Transdiagnostic Case Stories
Introduction to the basic principles of
cognitive therapy and importance of
managing thoughts to manage MDD.
Instructions for monitoring and
challenging thoughts. MDD  speciﬁc
vignettes and examples of thoughts
provided.
– Thought monitoring
– Thought challenging
– Structured problem
solving
– Challenging beliefs
–  MDD Case Stories
3  Introduction to the physical symptoms of
hyper-arousal and hypo-arousal and their
relationship to anxiety and low mood.
Instructions about controlling physical
symptoms using de-arousal strategies such
as controlled breathing and scheduling
pleasant activities. Transdiagnostic
vignettes and examples of physical
symptoms provided.
– Controlled relaxation
– Pleasant activity
scheduling
– Risk Calculation, Coping
Calculation and Shifting
Attention
– 100 pleasant things to do
–  Transdiagnostic Case Stories
Introduction to the physical symptoms
of hypo-arousal and their relationship
to MDD. Instructions about controlling
physical symptoms by scheduling
pleasant activities and light physical
activities. MDD  speciﬁc vignettes and
examples of physical symptoms
provided.
– Activity scheduling – 100 pleasant things
to do
– MDD Case Stories
4  Introduction to the behavioural symptoms
of anxiety and low mood. Explanation of
avoidance and safety behaviours and their
relationship to ongoing distress.
Instructions for graded exposure for safely
confronting fears and increasing activity
levels. Transdiagnostic vignettes and
examples of graded exposure provided.
– Graded exposure – Assertive communication
–  Transdiagnostic Case Stories
Introduction to the behavioural
symptoms of MDD. Explanation of
avoidance and safety behaviours for
MDD. Instructions for graded
behavioural activation for increasing
daily activities. MDD  speciﬁc vignettes
and examples of graded exposure
provided.
– Graded behavioural
activation for
increasing activities
–  Assertive
communication
–  MDD Case Stories
5  Information about the occurrence of lapses
and the process of recovery from anxiety
and low mood. Information about the signs
of  relapse and managing lapses.
Instructions for creating a relapse
prevention plan. Transdiagnostic vignettes
and examples of lapses and lapse
management provided.
– Relapse prevention – Transdiagnostic Case Stories Information about the occurrence of
lapses and the process of recovery
from MDD. Information about the signs
of relapse and managing lapses.
Instructions for creating a relapse
prevention plan. MDD  speciﬁc
vignettes and examples of lapses and
lapse management provided.
– Relapse prevention - MDD  Case Stories
Note: The transdiagnostic course was  designed in such a way  that no speciﬁc anxiety or depressive disorder was mentioned throughout the materials, vignettes, examples and case stories. The disorder speciﬁc course made
speciﬁc  mention of MDD  and the materials, vignettes, examples and case stories all focussed on MDD.
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There were also signiﬁcant differences between the groups at theN. Titov et al. / Journal of An
hange was small and constrained to one time period and to one
easure, this higher order interaction was not further analysed.
.2. Transdiagnostic CBT (TD-CBT) versus disorder-speciﬁc CBT
DS-CBT)
The means, percentage reductions and effect sizes for the TD-
BT and DS-CBT groups are shown in Table 3.
.2.1. Outcomes across the diagnoses
.2.1.1. Major depressive disorder. Among those meeting diagnostic
riteria for MDD  (n = 217) the GEE analyses indicated a signiﬁcant
ffect for Time (PHQ-9: Wald’s 2 = 468.12, p < .001) but no signiﬁ-
ant Time by Treatment Approach interaction effect for depressive
ymptoms (PHQ-9: Wald’s 2 = 3.16, p = .532). Pairwise compar-
sons indicated that both groups improved similarly from baseline
o post-treatment (p < .001) with no other signiﬁcant changes
etween the other time points.
.2.1.2. Generalised anxiety disorder. Among those meeting diag-
ostic criteria for GAD (n = 152) the GEE analyses indicated a
igniﬁcant effect for Time (GAD-7: Wald’s 2 = 289.44, p < .001)
ut no signiﬁcant Time by Treatment Approach interaction for
AD symptoms (GAD-7: Wald’s 2 = 6.98, p = .137). Pairwise com-
arisons indicated that both groups improved similarly from
aseline to post-treatment (p < .001) and from post-treatment to 3-
onth follow-up (p = .045). There were no other signiﬁcant changes
etween the other time points.
.2.1.3. Social anxiety disorder. Among those meeting diagnostic
riteria for SAD (n = 95) the GEE analyses indicated a signiﬁcant
ffect for Time (MINI-SPIN: Wald’s 2 = 126.03, p < .001) but no
igniﬁcant Time by Treatment Approach interaction for social
nxiety symptoms (MINI-SPIN: Wald’s 2 = 5.84, p = .211). Pair-
ise comparisons indicated that both groups improved similarly
rom baseline to post-treatment (p < .001) and that both group’s
ymptoms worsened slightly from 12-month follow-up to 24-
onth follow-up (p = .030). There were no other signiﬁcant changes
etween the other time points.
.2.1.4. Panic disorder. Among those meeting diagnostic criteria
or PD (n = 45) the GEE analyses indicated a signiﬁcant effect for
ime (PDSS-SR: Wald’s 2 = 34.37, p < .001) and a signiﬁcant Time
y Treatment Approach interaction for panic symptoms (PDSS-SR:
ald’s 2 = 11.10, p = .025). Pairwise comparisons indicated that
oth groups improved from baseline to post-treatment (p < .001)
nd that the TD-CBT group further improved between 3-month and
2-month follow-up (p < .001). However, the pairwise comparisons
evealed there were no signiﬁcant differences between the TD-CBT
nd DS-CBT groups at any time point (ps > .05).
.2.2. Outcomes for general psychological distress, disability, and
euroticism
Across the whole sample (n = 290) the GEE analyses indicated
 signiﬁcant effect for Time (K10: Wald’s 2 = 549.50, p < .001) and
 signiﬁcant Time by Treatment Approach interaction for general
sychological distress (K10: Wald’s 2 = 9.27, p = .026). Pairwise
omparisons indicated that both groups improved from baseline
o post-treatment (p < .001) and that the TD-CBT group further
mproved from post-treatment to 3-month follow-up (p < .001). At
ost-treatment the TD-CBT group reporting slightly lower psycho-
ogical distress than the DS-CBT group (p = .011). However, there
ere no differences at 3-month or 12-month follow-up (p > .05).
Across the whole sample (n = 290) there was a signiﬁcant
ffect for Time (SDS: Wald’s 2 = 380.54, p < .001) but no signiﬁ-
ant Time by Treatment Approach interaction for disability (SDS:isorders 35 (2015) 88–102 95
Wald’s 2 = 9.02, p = .061). Pairwise comparisons indicated that
both groups improved from baseline to post-treatment (p < .001)
and from post-treatment to 3-month follow-up (p = .025).
Across the whole sample (n = 290) there was  a signiﬁcant effect
for Time (NEO-FFI-N: Wald’s 2 = 291.59, p < .001) but no signiﬁcant
Time by Treatment Approach interaction for neuroticism (NEO-FFI-
N: Wald’s 2 = 2.42, p = .490). Pairwise comparisons indicated that
both groups improved from baseline to post-treatment and from
post-treatment to 3-month follow-up (ps < .001).
3.2.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
meeting formal diagnostic criteria at initial assessment and 3-
month follow-up are shown in Table 5. The GEE  analyses of
diagnoses revealed a signiﬁcant effect for Time across the diag-
noses (MDE; Wald’s 2 = 206.28, p < .001; GAD: Wald’s 2 = 112.12,
p < .001; SAD: Wald’s 2 = 28.505, p < .001) with the exception of
panic disorder (PD: Wald’s 2 = 1.22, p = .269). No signiﬁcant Time
by Treatment Approach interactions were observed for any diag-
noses (MDE: Wald’s 2 = 0.36, p = .546; GAD: Wald’s 2 = 2.21,
p = .137; SAD: Wald’s 2 = 0.01, p = .917; PD: Wald’s 2 = 0.04,
p = .838) indicating that the proportion of participants meeting
diagnostic criteria, except for PD, signiﬁcantly reduced across time
irrespective of Treatment Approach.
The GEE analyses focusing on average comorbid diagnoses
revealed a signiﬁcant Time effect (Wald’s 2 = 102.94, p < .001) but
no Time by Treatment Approach interaction (Wald’s 2 = 3.143,
p = .076). These analyses indicated signiﬁcant reductions in comor-
bid diagnoses amongst both the TD-CBT and DS-CBT groups over
time.
3.2.4. Treatment completion and satisfaction rates
There was a small difference in the number of lessons read
by the TD-CBT (M = 3.89; SD = 1.21) and DS-CBT groups (M = 4.26;
SD = 1.43) at post-treatment (F1,288 = 5.61, p < .05). Of the partici-
pants that completed the evaluation questions at post- treatment,
92% (100/109) of the TD-CBT group and 96% (108/113) of the DS-
CBT group, reported they would recommend the course to others.
Moreover, 96% (104/108) of the TD-CBT group and 97% (110/113)
of the DS-CBT group reported participating in the course was
worth their time. There were no signiﬁcant differences between
the groups in the proportions of participants who  reported they
would recommend the course or reporting ﬁnding the course was
worth their time (2 range = .20 to 1.38; p range = .240–.656).
3.3. Clinician-guided CBT (CG-CBT) versus self-guided CBT
(DS-CBT)
The means, standard deviations and effect sizes for the CG-CBT
and SG-CBT groups are shown in Table 4.
3.3.1. Outcomes across the diagnoses
3.3.1.1. Major depressive disorder. Among those meeting diagnostic
criteria for MDD  (n = 217) the GEE analyses indicated a signif-
icant effect for Time (PHQ-9: Wald’s 2 = 480.51, p < .001) and
a signiﬁcant Time by Treatment Approach interaction effect for
depressive symptoms (PHQ-9: Wald’s 2 = 15.33, p = .004). Pairwise
comparisons indicated that both groups improved similarly from
baseline to post-treatment (p < .001) and that the SG-CBT group fur-
ther improved from 12-month to 24-month follow-up (p = .026).3-month (p = .044) and 12-month follow-ups (p < .001), with the
CG-CBT group reporting signiﬁcantly lower symptoms at each time
point. No other signiﬁcant changes were observed over time or
between the two groups.
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Table 3
Means, percentage change and effect sizes: transdiagnostic (TD-CBT) versus disorder speciﬁc (DS-CBT)
Estimated  marginal  means %  change  from  baseline Within  group  Cohen’s  d  from  baseline Between  group  Cohen’s  d
Baseline  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth
Principal  outcome
Depression  symptomsa
DS-CBT  (n  =  108)  15.00,  (3.78)
[14.30,  15.73]
7.36  (4.75)
[6.52,  8.31]
6.72  (5.07)
[5.83,  7.75]
6.75  (4.64)
[5.93,  7.68]
6.86  (4.86)
[6.00,  7.84]
51%
[45%,  57%]
55%
[48%,  61%]
55%
[49%,  61%]
54%
[48%,  60%]
1.78
[1.46,  2.09]
1.85
[1.53,  2.16]
1.95
[1.62,  2.27]
1.87
[1.54,  2.18]
−.20
[−.47,  .06]
−.21
[−.48,  .05]
−.18
[−.45,  .08]
−.07
[−.34,  .20]
TD-CBT (n  =  109) 15.29,  (3.62)
[14.63,  15.99]
8.40,  (5.41)
[7.45, 9.48]
7.85  (5.47)
[6.88,  8.94]
7.66  (5.22)
[6.74,  8.71]
7.21  (5.11)
[6.32,  8.24]
45%
[38%,  51%]
49%
[42%,  55%]
50%
[43%,  56%]
53%
[46%,  59%]
1.50
[1.19,  1.79]
1.60
[1.29,  1.90]
1.70
[1.38,  2.00]
1.82
[1.50,  2.13]
Secondary outcomes
Generalised  anxiety  symptomsb
DS-CBT  (n  =  70)  11.70,  (4.25)
[10.75,  12.74]
6.67  (4.36)
[5.72,  7.77]
5.14  (4.176)
[4.25,  6.22]
5.86  (4.05)
[4.98,  6.89]
5.20  (3.27)
[4.49, 6.02]
43%
[34%,  51%]
56%
[47%,  64%]
50%
[41%,  57%]
56%
[49%,  62%]
1.17
[.80,  1.52]
1.56
[1.17,  1.93]
1.41
[1.03,  1.77]
1.71
[1.32,  2.09]
.08
[-.24,  .39]
−.30
[-.62,  .02]
.05
[-.27,  .37]
−.02
[-.34, .30]
TD-CBT (n  =  82)  11.40,  (4.28)
[10.51,  12.37]
6.35  (4.09)
[5.53,  7.30]
6.49  (4.81)
[5.33,  7.62]
5.66  (4.33)
[4.80,  6.68]
5.29  (4.26)
[4.44,  6.29]
44%
[36%,  52%]
43%
[33%,  52%]
50%
[41%,  58%]
54%
[45%,  61%]
1.21
[.87,  1.53]
1.08
[.75,  1.40]
1.33
[.99,  1.67]
1.43
[1.08,  1.77]
Social anxiety  symptomsc
DS-CBT  (n  =  36)  7.00  (2.74)
[6.16, 7.96]
4.71  (2.76)
[3.89,  5.70]
4.04  (2.33)
[3.35,  4.88]
4.41  (2.92)
[3.56,  5.48]
4.95  (3.19)
[4.01,  6.11]
33%
[19%,  44%]
42%
[30%,  52%]
37%
[22%,  49%]
29%
[13%,  43%]
.83
[.34,  1.30]
1.16
[.65,  1.65]
.91
[.42,  1.39]
.69
[.21,  1.16]
−.23
[−.64,  .19]
−.41
[−.83,  .01]
−.07
[−.49,  .34]
−.13
[−.54,  .29]
TD-CBT (n  =  59)  8.05  (2.69)
[7.39, 8.77]
5.43  (3.33)
[4.64,  6.35]
5.35  (3.59)
[4.51,  6.35]
4.64  (3.18)
[3.89,  5.53]
5.37  (3.25)
[4.60,  6.27]
33%
[21%,  42%]
34%
[21%,  44%]
42%
[31%,  52%]
33%
[22%,  43%]
.87
[.48,  1.24]
.85
[.47,  1.22]
1.16
[.76,  1.54]
.90
[.51,  1.27]
Panic symptomsd
DS-CBT  (n  =  18)  8.00  (4.97)
[6.01,  10.66]
5.17  (3.93)
[3.64,  7.35]
4.65  (4.67)
[2.93,  7.40]
5.44  (4.22)
[3.80,  7.78]
4.51  (5.40)
[2.59,  7.84]
35%
[8%,  54%]
42%
[8%,  63%]
32%
[3%,  53%]
44%
[2%,  68%]
.63
[−.05,  1.29]
.69
[.01,  1.35]
.56
[−.12,  1.21]
.67
[−.01,  1.33]
−.17
[−.77,  .43]
−.30
[−.89,  .31]
.41
[−.20,  1.00]
−.03
[−.62,  .57]
TD-CBT (n  =  27)  9.45  (6.16)
[7.39, 12.08]
6.03  (5.50)
[4.28, 8.50]
6.36  (6.36)
[4.36,  9.27]
3.68  (4.36)
[2.36,  5.76]
4.65  (5.46)
[2.99,  7.24]
36%
[10%,  55%]
33%
[2%,  54%]
61%
[39%,  75%]
51%
[23%,  68%]
.58
[.03,  1.12]
.49
[-.05,  1.03]
1.08
[.50,  1.64]
.82
[.26,  1.37]
Tertiary outcomes
Disability and  functioning  (SDS)
DS-CBT  (n  =  141)  14.73  (7.92)
[13.48,  16.10]
7.79  (6.79)
[6.74,  8.99]
7.14  (7.06)
[6.06,  8.40]
6.92  (6.59)
[5.91,  8.10]
6.08  (6.11)
[5.15, 7.18]
47%
[39%,  54%]
52%
[43%,  59%]
53%
[45%,  60%]
59%
[51%,  65%]
.94
[.69,  1.18]
1.01
[.76,  1.26]
1.07
[.82,  1.32]
1.22
[.97,  1.47]
−.20
[−.43,  .03]
−.13
[−.36,  .11]
−.13
[−.36,  .10]
−.17
[−.41,  .06]
TD-CBT (n  =  149) 14.21  (7.97)
[12.99,  15.55],
9.24  (7.63)
[8.09,  10.55]
8.06  (7.59)
[6.93,  9.37]
7.79  (7.13)
[6.73,  9.03]
7.22  (6.89)
[6.19,  8.41]
35%
[26%,  43%]
43%
[34%,  51%]
45%
[36%,  53%]
49%
[41%,  56%]
.64
[.40,  .87]
.79
[.55,  1.02]
.85
[.61,  1.08]
.94
[.70,  1.17]
Psychological distress  (K-10)
DS-CBT (n  =  141)  27.65  (7.19)
[26.49,  28.87]
19.62(6.72)
[18.55,  20.77]
19.26(7.19)
[18.11,  20.49]
18.99(6.89)
[17.88,  20.16]
– 29%
[25%,  33%]
30%
[26%,  35%]
31%
[27%,  35%]
– 1.15
[.90,  1.40]
1.17
[.91,  1.42]
1.23
[.97,  1.48]
–  −.30
[−.53,  −.07]
−.07
[-.30,  .16]
−.09
[−.32,  .14]
–
TD-CBT (n  =  149) 27.83  (7.16)
[26.71,  29.01]
21.68  (6.97)
[20.59,  22.83]
19.74  (7.34)
[18.60,  20.96]
19.59  (6.90)
[18.52,  20.73]
– 22%
[18%,  26%]
29%
[25%,  33%]
30%
[26%,  33%]
– .87
[.63,  1.11]
1.12
[.87,  1.36]
1.17
[.92,  1.41]
–
Neuroticism (NEO-FFI-N)
DS-CBT  (n  =  141)  31.70  (7.05)
[30.55,  32.88]
27.03  (7.50)
[25.82,  28.29]
25.25  (7.66)
[24.02,  26.55]
25.14  (8.42)
[23.79,  26.57]
– 15%
[11%,  19%]
20%
[16%,  24%]
21%
[16%,  25%]
– .64
[.40,  .88]
.88
[.63,  1.12]
.84
[.60,  1.09]
–  −.36
[−.59,  −.12]
−.39
[−.62,  −.16]
−.33
[−.56,  −.10]
–
TD-CBT (n  =  149)  34.02  (6.19)
[33.04,  35.03]
29.76  (7.81)
[28.54,  31.04]
28.29  (7.94)
[27.04,  29.59]
27.82  (7.66)
[26.62,  29.08]
– 13%
[9%,  16%]
17%
[13%,  21%]
18%
[15%,  22%]
– .60
[.37,  .84]
.80
[.57,  1.04]
.89
[.65,  1.13]
–
Note: Standard deviations are shown in rounded parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1-exp())  in the model.
Depression, generalised anxiety, social anxiety and panic symptoms were measured with the PHQ-9, GAD-7, MINI-SPIN, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for major depressive disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for generalised anxiety disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for social anxiety disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for panic disorder at assessment.
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Table 4
Means, percentage change and effect sizes: clinician-guided (CG-CBT) versus self-guided (SG-CBT).
Estimated  marginal  means  % change  from  baseline  Within  Group  Cohen’s  d from  baseline  Between  Group  Cohen’s  d
Baseline  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth
Principal  outcome
Depression  symptomsa
CG-CBT  (n =  112)  15.07  (3.57)
[14.43,  15.75]
7.36 (5.04)
[6.48, 8.36]
6.59  (4.98)
[5.73, 7.58]
6.05  (4.10)
[5.33, 6.85]
6.62 (4.79)
[5.79, 7.57]
51%
[45%,  57%]
56%
[50%,  62%]
60%
[55%,  65%]
56%
[50%,  62%]
1.77
[1.45,  2.07]
1.96
[1.63,  2.27]
2.35
[2.00,  2.68]
2.00
[1.67,  2.31]
−.21
[−.48,  .06]
−.27
[.54,  −.01]
−.50
[−.77,  −.22]
−.17
[−.44,  .09]
SG-CBT (n  =  105)  15.23  (3.85)
[14.51, 15.98]
8.44 (5.14)
[7.51, 9.48]
8.03  (5.53)
[7.04, 9.16]
8.44  (5.47)
[7.46, 9.56]
7.49 (5.16)
[6.56, 8.54]
45%
[38%,  51%]
47%
[40%,  54%]
45%
[37%,  51%]
51%
[44%,  57%]
1.50
[1.18,  1.80]
1.51
[1.20,  1.81]
1.44
[1.13,  1.73]
1.70
[1.38  2.01]
Secondary outcomes
Generalised  anxiety  symptomsb
CG-CBT  (n =  67)  11.61  (4.38)
[10.61, 12.71]
6.47 (4.29)
[5.52, 7.58]
5.93  (4.81)
[4.89, 7.20]
5.52  (3.93)
[4.65, 6.54]
5.32 (3.80)
[4.48, 6.31]
44%
[35%,  52%]
49%
[38%,  58%]
52%
[44%,  60%]
54%
[46%,  61%]
1.19
[.81,  1.55]
1.23
[.86,  1.60]
1.46
[1.07,  1.84]
1.53
[1.14,  1.91]
−.01
[−.33,  .31]
.02
[−.30,  .34]
−.10
[−.42,  .22]
.03
[−.29,  .35]
SG-CBT (n  =  85)  11.48  (4.18)
[10.63, 12.41]
6.52 (4.16)
[5.69, 7.47]
5.82  (4.38)
[4.96, 6.83]
5.93  (4.41)
[5.07,  6.95]
5.19  (3.86)
[4.43, 6.08]
43%
[35%,  50%]
49%
[41%,  57%]
48%
[39%,  56%]
55%
[47%,  61%]
1.19
[.86,  1.51]
1.32
[.98,  1.65]
1.29
[.96,  1.62]
1.56
[1.21,  1.90]
Social anxiety  symptomsc
CG-CBT  (n =  51)  7.61  (2.39)
[6.98, 8.29]
5.00  (2.76)
[4.29,  5.81]
4.47  (2.69)
[3.79, 5.28]
4.12  (2.49)
[3.49, 4.86]
4.99 (2.69)
[4.30,  5.78]
34%
[24%,  44%]
41%
[31%,  50%]
46%
[36%,  54%]
34%
[24%,  43%]
1.01
[.59,  1.42]
1.23
[.80,  1.65]
1.43
[.99,  1.85]
1.03
[.61,  1.43]
−.11
[−.51,  .30]
−.26
[−.66,  .15]
−.31
[−.71,  .10]
−.15
[−.55,  .26]
SG-CBT (n  =  44)  7.71  (3.13)
[6.83, 8.69]
5.34  (3.53)
[4.39, 6.49]
5.30  (3.72)
[4.31, 6.52]
5.06  (3.59)
[4.10,  6.24]
5.47  (3.75)
[4.47, 6.70]
31%
[16%,  43%]
31%
[15%,  44%]
34%
[19%,  47%]
29%
[13%,  42%]
.71
[.27,  1.13]
.70
[.26,  1.13]
.79
[.35,  1.21]
.65
[.21,  1.07]
Panic symptomsd
CG-CBT  (n =  22)  8.27  (4.08)
[6.73, 10.17]
5.71  (3.79)
[4.32, 7.53]
5.00  (4.22)
[3.51,  7.11]
3.87  (3.66)
[2.61, 5.75]
3.57 (4.28)
[2.16, 5.89]
31%
[9%,  48%]
40%
[14%,  58%]
53%
[31%,  68%]
57%
[29%,  74%]
.65
[.03,  1.24]
.79
[.16,  1.39]
1.14
[.48,  1.75]
1.12
[.47,  1.74]
.01
[−.58,  .59]
−.23
[−.81,  .36]
−.23
[−.81,  .36]
−.37
[−.96,  .22]
SG-CBT (n  =  23)  9.44  (6.95)
[6.98, 12.75]
5.67  (5.84)
[3.72, 8.64]
6.33  (6.93)
[4.05,  9.90]
4.87  (4.95)
[3.22, 7.38]
5.57 (6.19)
[3.54, 8.78]
40%
[8%,  61%]
33%
[-5%, 57%]
48%
[22%,  66%]
41%
[7%,  62%]
.59
[-.01,  1.17]
.45
[-.14,  1.03]
.76
[.15,  1.34]
.59
[-.01,  1.17]
Tertiary outcomes
Disability and  functioning  (SDS)
CG-CBT (n =  145)  14.00  (7.91)
[12.77,  15.35]
8.17 (6.80)
[7.13, 9.35]
7.28  (6.99)
[6.22, 8.51]
6.72  (6.53)
[5.74, 7.87]
5.81 (6.16)
[4.89, 6.90]
42%
[33%,  49%]
48%
[39%,  56%]
52%
[44%,  59%]
59%
[51%,  65%]
.79
[.55,  1.03]
.90
[.66,  1.14]
1.00
[.76,  1.25]
1.16
[.90,  1.40]
−.10
[9.33,  .13]
−.09
[−.32,  .14]
−.19
[−.42,  .04]
−.26
[−.49,  −.03]
SG-CBT (n  =  145)  14.93  (7.96)
[13.68, 16.28]
8.89 (7.69)
[7.73, 10.24]
7.94  (7.68)
[6.79, 9.30]
8.01  (7.16)
[6.93, 9.27]
7.52 (6.81)
[6.49, 8.72]
40%
[31%,  48%]
47%
[38%,  55%]
46%
[38%,  54%]
50%
[42%,  57%]
.77
[.53,  1.01]
.89
[.65,  1.13]
.91
[.67,  1.15]
1.00
[.75,  1.24]
Psychological distress  (K-10)
CG-CBT (n =  145)  27.50  (7.21)
[26.35,  28.70]
20.09  (6.81)
[19.01, 21.23]
18.96  (7.13)
[17.83,  20.15]
18.70  (6.67)
[17.64,  19.81]
– 27%
[23%,  31%]
31%
[27%,  35%]
32%
[28%,  36%]
–  1.06
[.81,  1.30]
1.19
[.94,  1.44]
1.27
[1.01,  1.52]
– −.17
[−.40,  .06]
−.15
[9.38,  .08]
−.17
[−.40, .06]
–
SG-CBT (n  =  145)  27.99  (7.13)
[26.86, 29.18]
21.27  (6.99)
[20.16, 22.44]
20.06  (7.37)
[18.90,  21.30]
19.90  (7.07)
[18.78,  21.08]
– 24%
[20%,  28%]
28%
[24%,  33%]
29%
[25%,  33%]
–  .95
[.71,  1.19]
1.09
[.84,  1.34]
1.14
[.89,  1.38]
–
Neuroticism (NEO-FFI-N)
CG-CBT  (n =  145)  31.93  (6.95)
[30.81, 33.08]
27.77  (7.97)
[26.50, 29.10]
26.39  (7.99)
[25.13,  27.73]
26.39  (8.86)
[24.99,  27.87]
– 13%
[9%,  17%]
17%
[13%,  21%]
17%
[13%,  22%]
–  .56
[.32,  .79]
.74
[.50,  .98]
.70
[.46,  .93]
– −.17
[−.40,  .06]
−.11
[−.34,  .12]
−.03
[−.26,  .20]
–
SG-CBT (n  =  145)  33.86  (6.34)
[32.84, 34.90]
29.10  (7.53)
[27.90, 30.35]
27.23  (7.88)
[25.98,  28.55]
26.65  (7.38)
[25.47,  27.88]
– 14%
[10%,  18%]
20%
[16%,  23%]
21%
[18%,  25%]
–  .68
[.45,  .92]
.93
[.68,  1.17]
1.05
[.80,  1.29]
–
Note: Standard deviations are shown in rounded parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1 - exp()) in the
model.
Depression, generalised anxiety, social anxiety and panic symptoms were measured with the PHQ-9, GAD-7, MINI-SPIN, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for major depressive disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for generalised anxiety disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for social anxiety disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for panic disorder at assessment.
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Table 5
Proportions meeting diagnostic criteria over time for each of the groups.
TD-CBT versus DS-CBT CG-CBT versus SG-CBT
Baseline 3mth % change from baseline Baseline 3mth % change from baseline
TD-CBT DS-CBT TD-CBT DS-CBT TD-CBT DS-CBT CG-CBT SG-CBT CG-CBT SG-CBT CG-CBT SG-CBT
Diagnosis
Major
depressive
disorder
73%
[65%, 80%]
77%
[69%, 83%]
10%
[6%, 16%]
9%
[5%, 15%]
86%
[78%, 92%]
88%
[80%, 93%]
77%
[70%, 83%]
72%
[65%, 79%]
8%
[4%, 13%]
12%
[7%, 18%]
90%
[83%, 94%]
84%
[75%, 90%]
Generalised
anxiety
disorder
55%
[47%,  63%]
50%
[41%, 58%]
21%
[15%, 28%]
11%
[7%, 18%]
62%
[49%, 73%]
77%
[64%, 86%]
46%
[38%, 54%]
59%
[50%, 66%]
13%
[9%, 20%]
19%
[14%, 27%]
72%
[58%, 82%]
67%
[55%, 77%]
Social  anxiety
disorder
40%
[32%, 48%]
26%
[19%, 33%]
23%
[32%, 48%]
14%
[9%, 21%]
41%
[22%, 56%]
44%
[18%, 63%]
35%
[28%, 43%]
30%
[23%, 38%]
21%
[15%, 29%]
17%
[11%, 24%]
39%
[18%, 56%]
45%
[23%, 63%]
Panic  disorder 18%
[13%, 25%]
13%
[8%, 19%]
16%
[13%, 25%]
11%
[7%, 17%]
11%
[-26%, 39%]
17%
[-32%, 49%]
15%
[10%, 22%]
16%
[11%, 23%]
14%
[10%, 21%]
12%
[8%, 19%]
5%
[-40%, 36%]
22%
[-19%, 50%]
Comorbid diagnoses
Average 1.1
[0.9, 1.3]
0.9
[0.7, 1.0]
0.6
[0.5, 0.7]
0.4
[0.3, 0.5]
46%
[34%, 56%]
59%
[45%, 69%]
1.0
[0.8, 1.1]
1.0
[0.9, 1.2]
0.5
[0.4, 0.6]
0.5
[0.4, 0.6]
49%
[35%, 60%]
54%
[42%, 64%]
Frequencya
0 18%
[13%, 25%]
17%
[12%, 24%]
65%
[57%, 72%]
74%
[66%, 80%]
– – 19%
[14%, 27%]
16%
[11%, 23%]
73%
[65%, 80%]
66%
[57%, 73%]
– –
1  30%
[23%, 37%]
33%
[26%, 42%]
24%
[18%, 32%]
22%
[16%, 30%]
– – 31%
[24%, 39%]
32%
[25%, 40%]
20%
[14%, 27%]
26%
[20%, 34%]
– –
2  40%
[33%, 48%]
43%
[35%, 52%]
9%
[6%, 15%]
4%
[1%, 8%]
– – 41%
[34%, 50%]
42%
[34%, 50%]
6%
[3%, 11%]
8%
[4%, 13%]
– –
3  12%
[8%, 18%]
6%
[3%, 12%]
1%
[0%, 5%]
1%
[0%, 5%]
– – 8%
[5%, 14%]
10%
[6%, 16%]
1%
[0%, 5%]
1%
[0%, 5%]
– –
Note: 95% conﬁdence intervals of estimates are shown in parentheses both for estimates of proportions of participants meeting diagnostic criteria and for percentage change.
a The frequency of comorbid diagnoses over time was  estimated employing binary logistic regressions to provide estimates of frequency with 95% conﬁdence intervals rather than simple raw counts.
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.3.1.2. Generalised anxiety disorder. Among those meeting diag-
ostic criteria for GAD (n = 152) the GEE analyses indicated a
igniﬁcant effect for Time (GAD-7: Wald’s 2 = 290.19, p < .001)
ut no signiﬁcant Time by Treatment Approach interaction for
AD symptoms (GAD-7: Wald’s 2 = .930, p = .920). Pairwise com-
arisons indicated that both groups improved similarly from
aseline to post-treatment (p < .001). There were no other signif-
cant changes between the other time points.
.3.1.3. Social anxiety disorder. Among those meeting diagnostic
riteria for SAD (n = 95) the GEE analyses indicated a signiﬁcant
ffect for Time (MINI-SPIN: Wald’s 2 = 128.15, p <.001) but no
igniﬁcant Time by Treatment Approach interaction for social anx-
ety symptoms (MINI-SPIN: Wald’s 2 = 4.12, p = .390). Pairwise
omparisons indicated that both groups improved similarly from
aseline to post-treatment (p < .001) and that both group’s symp-
oms worsened slightly from 12-month follow-up to 24-month
ollow-up (p = .023).
.3.1.4. Panic disorder. Among those meeting diagnostic criteria
or PD (n = 45) the GEE analyses indicated a signiﬁcant effect for
ime (PDSS-SR: Wald’s 2 = 36.60, p < .001) but no signiﬁcant Time
y Treatment Approach interaction for panic symptoms (PDSS-
R: Wald’s 2 = 2.64, p = .620). Pairwise comparisons indicated that
oth groups improved from baseline to post-treatment (p < .001).
here were no differences between the TD-CBT and DS-CBT groups
t any other time points (ps > .05).
.3.2. Outcomes for general psychological distress, disability, and
euroticism
Across the whole sample (n = 290) the GEE analyses indicated
 signiﬁcant effect for Time (K10: Wald’s 2 = 547.84, p < .001) but
o signiﬁcant Time by Treatment Approach interaction for general
sychological distress (K10: Wald’s 2 = 2.12, p = .547). Pairwise
omparisons indicated that both groups improved from baseline
o post-treatment (p < .001) and from post-treatment to 3-month
ollow-up (p = .002).
Across the whole sample (n = 290) there was a signiﬁcant
ffect for Time (SDS: Wald’s 2 = 373.41, p < .001) but no signiﬁ-
ant Time by Treatment Approach interaction for disability (SDS:
ald’s 2 = 3.90, p = .419). Pairwise comparisons indicated that
oth groups improved from baseline to post-treatment (p < .001)
nd from post-treatment to 3-month follow-up (p = .021).
Across the whole sample (n = 290) there was  a signiﬁcant effect
or Time (NEO-FFI-N: Wald’s 2 = 289.63, p < .001) but no signiﬁcant
ime by Treatment Approach interaction for neuroticism (NEO-FFI-
: Wald’s 2 = 3.05, p = .384). Pairwise comparisons indicated that
oth groups improved from baseline to post-treatment and from
ost-treatment to 3-month follow-up (ps < .001).
.3.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
eeting formal diagnostic criteria at initial assessment and 3-
onth follow-up are shown in Table 5. The GEE analyses of
iagnoses revealed a signiﬁcant effect for Time across the diag-
oses (MDE; Wald’s 2 = 204.97, p < .001; GAD: Wald’s 2 = 224.67,
 < .001; SAD: Wald’s 2 = 30.134, p < .001) with the exception of
anic disorder (PD: Wald’s 2 = 1.238, p = .266). No signiﬁcant Time
y Treatment Approach interactions were observed for any diag-
oses (MDE: Wald’s 2 = 2.483, p = .115; GAD: Wald’s 2 = 0.860,
 = .353; SAD: Wald’s 2 = 0.127, p = .727; PD: Wald’s 2 = 0.570,
 = .450) indicating that the proportion of participants meeting
iagnostic criteria, except for PD, signiﬁcantly reduced across time
rrespective of Treatment Approach.
The GEE analyses focused on average comorbid diagnoses
evealed a signiﬁcant Time effect (Wald’s 2 = 108.26, p < .001) butisorders 35 (2015) 88–102 99
no Time by Treatment Approach interaction (Wald’s 2 = 0.476,
p = .490). These analyses indicated signiﬁcant reductions in comor-
bid diagnoses amongst both the CG-CBT and SG-CBT groups over
time.
3.3.4. Treatment completion and satisfaction rates
There was no difference in the number of lessons completed by
the CG-CBT (M = 4.21; SD = 1.21) and SG-CBT (M = 3.92; SD = 1.44)
groups at post-treatment (F1,288 = 3.59, p = .059). Of  the participants
who completed the evaluation questions at post- treatment, 93%
(102/110) of the CG-CBT group, and 95% (106/112) of the SG-CBT
group, reported they would recommend the course to others. Further,
96% (106/110) of the CG-CBT group and 97% (108/111) of the SG-
CBT group reported the course was worth their time. There were no
signiﬁcant differences in the proportions of participants willing to
recommend the course or ﬁnding the course was worth their time
(2 range: .16–.35; p = .557–.692).
4. Discussion
The present study compared the efﬁcacy of transdiagnostic and
disorder-speciﬁc CBT for MDD  when provided with and without
regular clinician contact. The hypotheses were not fully supported.
TD- CBT and DS-CBT were both associated with signiﬁcant improve-
ments in symptoms of MDD  as well as signiﬁcant improvements
in comorbid symptoms of GAD, SAD and PD. Gains were main-
tained at 24-month follow-up. Similarly, the CG-CBT and SG-CBT
resulted in signiﬁcant improvements in symptoms of MDD  and
signiﬁcant improvements in comorbid symptoms and again, these
improvements were stable at 24-month follow-up. Reﬂecting this,
signiﬁcant reductions in the proportions of participants meet-
ing diagnostic criteria for MDD, GAD and SAD, but not PD, were
observed across all conditions at three month follow-up. There was
some evidence of the CG-CBT group reporting marginally lower
symptoms than the SG-CBT group at two time points. However,
no marked or consistent differences were observed across the out-
comes either between TD-CBT or between DS-CBT groups or the
CG-CBT or SG-CBT groups. Treatment completion rates were also
similar across the groups and satisfaction rates were high.
The large reductions in principal symptoms of MDD  (Cohen’s
d ≥ 1.44; avg. reduction ≥ 45%) and in comorbid symptoms of GAD
(Cohen’s d ≥ 1.08; avg. reduction ≥ 43%), SAD (Cohen’s d ≥ 0.69; avg.
reduction ≥ 29%) and PD (Cohen’s d ≥ 0.49; avg. reduction ≥ 32%)
for both TD-CBT and DS-CBT are consistent with the magnitude
of clinical change reported in meta-analyses of the broader trans-
diagnostic and disorder-speciﬁc treatment literature (Butler et al.,
2006; McEvoy et al., 2009; Andrews et al., 2010; Reinholt & Krogh,
2014). These improvements were also reﬂected in signiﬁcantly
reduced proportions of participants meeting diagnostic criteria
for MDD  (reduction ≥ 86%), GAD (reduction ≥ 62%), SAD (reduc-
tion ≥ 41%), but not PD (reduction ≥ 11%), at 3-month follow-up
when participants again completed a diagnostic interview. The
present ﬁndings are consistent with an emerging body of litera-
ture indicating that different approaches, including transdiagnostic
(Titov et al., 2011) and tailored-treatments (Johansson et al., 2012)
can be used to treat principal and comorbid symptoms of MDD.
The present ﬁndings are also consistent with those of the few other
existing studies that have directly compared transdiagnostic with
disorder- speciﬁc treatments, but which also failed to ﬁnd consis-
tent differences between these models (Norton & Barrera, 2012;
Dear et al., in press). Thus, as reported elsewhere (Clark, 2009;
Andrews et al., 2010; Norton & Barrera, 2012; Titov et al., 2012;
Reinholt & Krogh, 2014), the present ﬁndings support the argument
that the main beneﬁt of TD-CBT may  be in reducing the need for
clinicians to be competent in multiple disorder-speciﬁc treatments
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nd may  also reduce the need for complex differential diagnoses for
he most common and comorbid diagnoses. However, this observa-
ion may  not apply to all disorders. For example, Craske et al. (2007)
eported that a transdiagnostic intervention was less effective than
 disorder-speciﬁc intervention at treating panic disorder, indicat-
ng that the principal disorder may  be an important moderating
ariable in determining choice of treatment. Thus, we note that it
s possible that different disorders will respond differently to TD-
BT interventions, and this will be explored further in the studies
hat are occurring in parallel to the present study, but which target
ther disorders, including panic disorder.
A surprising ﬁnding from the present study was that no con-
istent differences were observed between the clinical outcomes
f participants receiving weekly clinician contact and those who
eceived treatment in a self-guided format. Indeed, large reductions
ere observed in principal symptoms of MDD  (Cohen’s d ≥ 1.44;
vg. reduction ≥ 45%) as well as comorbid symptoms of GAD
Cohen’s d ≥ 1.19; avg. reduction ≥ 48%), SAD (Cohen’s d ≥ 0.65; avg.
eduction ≥ 29%) and PD (Cohen’s d ≥ 0.45; avg. reduction ≥ 31%)
cross the CG-CBT and SG-CBT groups. These improvements
ere reﬂected in signiﬁcantly reduced proportions of participants
eeting diagnostic criteria for MDD  (reduction ≥ 84%), GAD (reduc-
ion ≥ 67%), SAD (reduction ≥ 39%), but not PD (reduction ≥ 5%).
hese ﬁndings are inconsistent with results of reviews that have
ound that clinician-guided treatment is associated with better
dherence and treatment outcomes than self-guided interventions
Richards & Richardson, 2012). This may  reﬂect the increased effec-
iveness of recently reported self-guided interventions (Berger et
l., 2011; Meyer et al., 2015; Dear et al., 2015), which include
herapist-administered diagnostic- screening prior to treatment,
rientation procedures and high quality treatment materials, fac-
ors that have been recognised as important components of
ffective contemporary self-guided interventions (Andersson &
itov, 2014). Thus, the efﬁcacy of the self-guided groups in the
resent trial should not be taken to indicate that therapists are not
equired. Rather, these results indicate that, providing treatment
aterials are of a high quality, some participants may  not require
herapist-contact during treatment. In order to provide appropri-
te clinical governance and to facilitate patient safety in the event
f deterioration, we propose that such patients still require initial
nd post-treatment interviews, as well as monitoring of progress
uring treatment. This has important implications for the broader
mplementation of online interventions as it provides support for
 cost-effective, yet potentially clinically safer and more clinically
ffective model than entirely automated self- guided treatments.
Signiﬁcant improvements were also observed in general
sychological distress (Cohen’s d ≥ 0.87; avg. reduction ≥ 22%), dis-
bility (Cohen’s d ≥ 0.64; avg. reduction ≥ 35%) and neuroticism
Cohen’s d ≥ 0.56; avg. reduction ≥ 13%) across the TD-CBT and DS-
BT as well as the CG-CBT and SG-CBT groups. This is encouraging
nd suggests that these treatments not only reduce principal and
omorbid symptoms but also several vulnerability factors for psy-
hological disorder. Of note, and consistent with recent reports
Dear et al., in press), we observed signiﬁcant and sustained reduc-
ions in the personality trait of neuroticism, consistent with recent
ndings that indicate this trait may  indeed by modiﬁed with treat-
ent (Johansson et al., 2013). In a recent study of transdiagnostic
roup therapy for anxiety disorders, Talkovsky and Norton (2014)
ound that negative affect, which is closely related to neuroticism,
ediated change in symptoms and that this indirect effect was
ot moderated by principal diagnosis. Thus, the degree to which
n intervention modiﬁes the vulnerability factors of neuroticism
r negative affectivity may  be crucial in producing symptomatic
elief for principal and comorbid disorders, regardless of whether
he intervention is diagnosis-speciﬁc or transdiagnostic per se. This
s important given that neuroticism is a strong predictor of healthisorders 35 (2015) 88–102
service use, impairment, and psychiatric morbidity and is associ-
ated with considerable economic costs (Lahey, 2009; Cuijpers et al.,
2010).
The present study has several important strengths and extends
the existing literature in a number of important ways. First, it is
the largest study to directly compare TD-CBT and DS-CBT as well
as CG-CBT and DS-CBT for MDD  and comorbid anxiety disorders.
Second, the present study employed two  treatment protocols that
are similar in structure and format enabling a more direct com-
parison of the different treatment approaches while controlling for
the issue of treatment dose. Thus, the design restricts the differ-
ences between the conditions and reduces some potential threats
to validity of the results. Third, the present study included long-
term follow-up, which enabled detection of potential longer-term
differences between the conditions, and it also obtained relatively
high response rates providing further conﬁdence in the results.
Fourth, the present study examined multiple outcomes (e.g., clini-
cal symptoms, diagnostic assessments, satisfaction and treatment
completion) to provide a broad evaluation of the interventions.
Despite these strengths there are some limitations that need to
be considered. The ﬁrst is the absence of a waitlist control group,
which would have provided a control for spontaneous remission. A
control group was not included within the trial for the reasons that
the magnitude of clinical changes of previous control groups using
similar methodologies has been negligible (e.g., range of Cohen’s
ds < 0.15; Titov et al., 2011; Titov et al., 2013; Titov et al., 2014;
Titov et al., 2015) and withholding treatment would therefore be
ethically questionable. Another important limitation is that, despite
the relatively large overall sample size, the current trial managed
to recruit only a small number of participants (n = 45; 15% of the
sample) with comorbid PD. Unfortunately, this may  have resulted
in a ﬂoor effect with the result that the present study had relatively
low power for detecting improvements in the proportion of par-
ticipants meeting criteria for PD. Alternatively, it may  be that the
treatments employed are not effective for comorbid PD; however,
this would seem unlikely given the signiﬁcant reductions in panic
symptoms observed among participants with PD. Nevertheless, this
is an important issue because, in order to be broadly adopted, TD-
CBT treatments need to be at least as effective as DS-CBT treatments
for the most common mental disorders and, to date, some trials
have suggested that transdiagnostic treatments may not to be as
effective as DS-CBT for PD (Craske et al., 2007). Future large scale
research is needed to explore this issue and to replicate and build
upon the ﬁndings of the current trial, especially for SAD and PD. The
authors are currently completing trials for these disorders. A third
limitation relates to the nature of the therapist-guided condition. It
is important to acknowledge that in an attempt to maximize ﬁdelity
and to reduce therapist drift, the nature and duration of therapist
contact was  limited and deﬁned by a carefully developed protocol.
This resulted in short weekly contacts, which may  have inadver-
tently reduced the potential beneﬁts of the therapist conditions,
although it should be noted that both self and therapist-guided
conditions resulted in large and signiﬁcant improvements in target
symptoms.
In conclusion, the present study found large clinical improve-
ments in symptoms of MDD  and comorbid GAD, SP and PD in both
the TD-CBT and DS-CBT as well as the CG-CBT and SG-CBT groups.
These improvements were maintained at 24-month follow-up and
were reﬂected in reductions in the proportions of participants
meeting diagnostic criteria for these disorders post-treatment
and in reductions in the levels of diagnostic comorbidity. The
treatments were associated with satisfactory levels of treatment
completion and high levels of treatment satisfaction. It remains to
be seen whether the TD-CBT intervention is as effective as DS-CBT
for other disorders. The other RCTs we  are conducting will help
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